The FDA’s April 2, 2026 Warning Letter to a cosmetics company marks a defining moment for the regulated industry, not because artificial intelligence (AI) was used in this firm’s operations, but because it was deployed without effective governance within a Pharmaceutical Quality System (PQS).

In this case, management relied on AI agents to draft GMP-critical regulatory documents, including drug product specifications, SOPs, and master production records. These AI-generated outputs were not adequately reviewed or approved by the Quality Unit (QU) to ensure that they were accurate and compliant with CGMP, resulting in violations of 21 CFR 211.22(c) and failures to establish appropriate production and process controls under 21 CFR 211.100. The FDA investigators documented that required validation activities were not performed because the organization “was not aware of the legal requirement” and believed the AI system itself would identify regulatory requirements.

The Agency’s message is unmistakable: technology does not shift accountability. The QU remains responsible for CGMP compliance, regardless of whether content is human- or AI-generated.

A Defining Thesis for the AI Era

A common misconception in biopharma is that organizations must wait for new FDA regulations before governing AI. We argue otherwise. This warning letter is precedent-setting precisely because it demonstrates that existing CGMP regulations already provide the necessary and enforceable framework for AI but only when properly integrated into the PQS.

As explored in Lachman’s Good AI Practice Meets Timeless cGMP, accelerated AI adoption is fully achievable today without new rulemaking when grounded in established principles of validation, data governance, oversight, documentation, and management responsibility. The regulations have not changed; the technology has.

Pragmatic Optimism and the Discipline It Requires

For a pragmatically optimistic leader, AI represents an unprecedented opportunity to enhance quality, not erode it, but only if deployed with discipline. That discipline arguably starts with investment in dual-literacy.

Staff must be trained to understand regulatory requirements and AI risks as well as the use of meaningful controls to mitigate those risks. Teams should be able to explain AI-supported outputs to an investigator with the same confidence and clarity used to defend chromatographic data, environmental monitoring results, or process validation strategies. If an AI system influenced a GMP decision, the organization, not the algorithm, must be able to explain how and why. This is not solely a technical challenge. It is an organizational one.

The Role of Cross-Functional Governance

This specific case also exposes a critical gap that many organizations share: insufficient AI literacy and communication across business operations, Quality, IT, and data science. When AI is adopted in silos, accountability fractures. Business teams may pursue efficiency, technical teams may focus on performance without knowledge of regulatory requirements, and Quality may be unable to explain the tool adequately, reacting after the fact, or worse… not even being aware of what was implemented.

Success requires a shared operating language and clear ownership. AI must be governed as part of a human-led quality culture, where oversight is intentional and responsibilities are explicit.

The Takeaway and the Path Forward

AI is your assistant, not your Quality Unit. As you look at your digital roadmap, the critical question is no longer which AI tools to leverage, but how you plan to govern them. Are you leading your digital transformation, or is an unvalidated algorithm quietly leading you toward non-compliance?

Lachman supports organizations by helping them:

  • Assess readiness for GMP-relevant AI use
  • Design AI governance programs embedded within the PQS
  • Build risk-based oversight and compliance models
  • Evaluate existing AI implementations
  • Train cross-functional teams to operate with both AI and quality literacy

The horizon has shifted. Organizations that integrate AI with discipline, transparency, and human accountability will move faster, and more safely, into the next era of regulatory scrutiny. Contact Lachman today at LCS@lachmanconsultants.com to see how we can help you integrate AI seamlessly into your quality systems.